Follicular Lymphoma Excellence Forum

Follicular Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Conference Coverage

Analyzing Patient Preferences on Follicular Lymphoma Treatment Delivery Options

01/16/2026

Krish Patel, MD

Krish Patel, MD, shared results from a patient preference study for relapsed/refractory follicular lymphoma at the 2025 ASH Annual Meeting & Exposition.

Krish Patel, MD, shared results...

01/16/2026

Oncology

Conference Coverage

Subcutaneous Mosunetuzumab Demonstrates Deep, Early Responses for Treatment-Naïve Follicular Lymphoma: Phase 2 MorningSun Trial

01/08/2026

John Burke, MD

John Burke, MD, reported that subcutaneous mosunetuzumab achieved high response rates and durable remissions with manageable toxicity for treatment-naïve, high-tumor burden follicular lymphoma.

John Burke, MD, reported that...

01/08/2026

Oncology

Conference Coverage

5-Year Data Show Durable Remissions With Tisagenlecleucel for R/R Follicular Lymphoma: ELARA Trial

01/08/2026

Stephen Schuster, MD

Stephen Schuster presented updated results from the phase 2 ELARA study which evaluated tisagenlecleucel among patients with relapsed/refractory follicular lymphoma.

Stephen Schuster presented...

01/08/2026

Oncology

Conference Coverage

Lisocabtagene Maraleucel Achieves High Responses and Durable 3-Year Remissions for R/R Follicular Lymphoma: TRANSCEND FL

12/07/2025

Sairah Ahmed, MD

For patients with at least 3 prior lines of therapy, lisocabtagene maraleucel produced durable, high response rates among patients with R/R follicular lymphoma, according to a 3-year update presented at the 2025 ASH Annual Meeting.

For patients with at least 3...

12/07/2025

Oncology

Videos

Emerging Targeted Therapies for Peripheral T-Cell Lymphoma

11/06/2025

Jia Ruan, MD, PhD

Jia Ruan, MD, shares insights into novel targeted therapies for patients with peripheral T-cell lymphoma at the 2025 Lymphoma, Leukemia, & Myeloma Congress.

Jia Ruan, MD, shares insights...

11/06/2025

Oncology

Videos

Emerging Treatments for Patients With Relapsed/Refractory Follicular Lymphoma

10/16/2025

Erin Mulvey, MD

Erin Mulvey, MD, discusses novel treatment options for patients with relapsed/refractory follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress.

Erin Mulvey, MD, discusses novel...

10/16/2025

Oncology

Videos

Strategies for Frontline Follicular Lymphoma Treatment and Curative Potential

10/15/2025

Emily Estrada

Jonathan Friedberg, MD, reviews recent clinical trial data and discusses strategies and progress in the treatment of patients with follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress.

Jonathan Friedberg, MD, reviews...

10/15/2025

Oncology

Videos

Analyzing the Benefits of Circulating Tumor DNA Testing for Patients With Lymphoma

10/15/2025

David Russler-Germain, MD, PhD

David Russler-Germain, MD, PhD, shares insights into the advantages of using circulating tumor DNA testing for patients with lymphoma to optimize patient care through genetic profiling and accurate disease activity testing.

David Russler-Germain, MD, PhD,...

10/15/2025

Oncology

Videos

Odronextamab Demonstrates Long-Term High Response Rates for Heavily Pretreated R/R Follicular Lymphoma: ELM-2

07/25/2025

Stefano Luminari, MD

At the EHA 2025 Congress, Stefano Luminari, MD shared results from the ELM-2 trial which evaluated the efficacy of odronextamab therapy for patients with relapsed/refractory follicular lymphoma with a follow-up of more than 2 years.

At the EHA 2025 Congress,...

07/25/2025

Oncology

Conference Coverage

New Therapeutic Updates for Patients With R/R Follicular Lymphoma

06/28/2025

Andrew M. Evens, DO, MSc

At the 2025 Great Debates (GD) in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discussed exciting new updates in the field of relapsed/refractory follicular lymphoma treatment, including the recent FDA approval of tafasitamab.

At the 2025 Great Debates (GD)...

06/28/2025

Oncology

Recent News

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology